Outlook for Pharma in 2018

The video discusses the anticipated developments in the pharmaceutical industry for 2018, focusing on large phase three trials in lung cancer by major companies like Rausch, Merck, and Bristol Myers. It highlights the market risks associated with these trials, particularly for Merck, and the potential impact of M&A activities and currency fluctuations. The video concludes with expectations for the upcoming JP Morgan healthcare conference.

What expectations are set for the year 2018 regarding drug trials and company performance?

Discuss the implications of currency strength on pharmaceutical companies as mentioned in the text.